(PharmaNewsWire.Com, September 13, 2019 ) Market Overview: Growth hormone deficiency (GHD) is a rare endocrine disorder that occurs due to impaired secretion of somatropin, a peptide growth hormone (GH) from the pituitary gland which is responsible for the growth and cell reproduction. GHD is classified into three categories: congenital, acquired, or idiopathic. Congenital GHD is present at the time of birth and can be caused either by genetic mutations or structural abnormality in the brain.
Market Dynamics: The market is driven by an increase in the incidences of GHD, the introduction of technologically advanced drugs with improved patient compliance and increased awareness of the disease. The high cost of treatment for GHD is the only reason that is expected to restrain the market growth over the period of forecast.
Market Segmentation: By Treatment Surgery Growth Hormone Therapy
By End User Hospitals Clinics Home Care Setting
By Distribution Channel Hospital pharmacies Retail pharmacies Online pharmacies
Geographical Analysis: By Geography, the market is segmented into: North America Europe South America Asia Pacific The Middle East and Africa
About Us: DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information: Sai Kiran Sales Manager at Data M Intelligence Email: info@datamintelligence.com Tel: +1 877 441 4866 Website: www.datamintelligence.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
